Combination of a parp-1 selective inhibitor and temozolimde and its use in the treatment of glioma

HK40137326APending Publication Date: 2026-09-11NERVIANO MEDICAL SERVICES SRL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026123814
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-10-09
Filing Date
2026-05-21
Publication Date
2026-09-11
Patent Text Reader

Abstract

The present invention provides a therapeutic combination comprising (a) an isoindole-piperidine compound of formula (I) as described in the specification and (b) an alkylating agent temozolomide wherein the active ingredient is present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof; and the use of the therapeutic combination in the treatment of glioma.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480064185.4 (22) Application Date 2024.10.04 (30) Priority Data 23202505.6 2023.10.09 EP (85) PCT International Application Entering National Phase Date 2026.04.03 (86) PCT International Application Application Data PCT / EP2024 / 077929 2024.10.04 (87) PCT International Application Publication Data WO2025 / 078276 EN 2025.04.17 (71) Applicant: Nelviano Medical Sciences Company Address: Nelviano, Milan, Italy (72) Inventors: A. Montagnoli, G.M.E. Papeo (74) Patent Agency: Beijing Anxin Fangda Intellectual Property Agency Co., Ltd. 11262 Patent Attorneys: Ling Cui, Zheng Xia (51) Int.Cl. A61K 31 / 454 (2006.01) A61K 31 / 495 (2006.01) A61P 35 / 00 (2006.01) (54) Invention Title: Combination of PARP-1 Selective Inhibitor and Temozolomide and Use Thereof in the Treatment of Glioma (57) Abstract: This invention provides a therapeutic combination comprising (a) an isoindole-piperidine compound of formula (I) as described in the specification and (b) an alkylating agent temozolomide, wherein the active ingredient is present in each case in a free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof; and the use of the therapeutic combination in the treatment of glioma. Claims 2 pages, Description 8 pages, CN 121969369 A 2026.05.01 CN 1 21 96 93 69 A 1. A treatment combination comprising: (a) a compound of formula (I): wherein R is hydrogen or fluorine, and (b) an alkylating agent temozolomide, for use in the treatment of glioma, wherein the active ingredient is present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof. 2. The treatment combination for use according to claim 1, wherein the compound of formula (I) is 2-(1-cyclohexylpiperidin-4-yl)-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (compound 1): . 3. The treatment combination for use according to any one of claims 1 or 2, wherein the glioma is glioblastoma. 4. The treatment combination for use according to any one of claims 1 to 3, for simultaneous, separate, or sequential administration. 5. The treatment combination for use according to any one of claims 1 to 4, wherein the combination is formulated as a pharmaceutical composition.6. The treatment combination for use according to any one of claims 1 to 5, in the form of a multi-part kit, the multi-part kit comprising: the agent (a) and the agent (b) in a suitable container, and instructions for use of the agent (a) and the agent (b) simultaneously, separately, or sequentially. 7. The treatment combination for use according to any one of claims 1 to 6, wherein the dose of the compound of formula (I) is from 1 mg / day to 1 g / day, and the dose of temozolomide is from 15 mg / m² to 300 mg / m² daily. 8. The treatment combination for use according to claim 7, wherein the dose of the compound of formula (I) is from 40 mg / day to 260 mg / day, and the dose of temozolomide is from 150 mg / m² to 200 mg / m² daily. 9. The treatment combination for use according to any one of claims 1 to 8, wherein the compound of formula (I) is administered orally. 10. A compound of formula (I) as defined in claim 1, used to reduce side effects caused by the alkylating agent temozolomide, said reduction of side effects being achieved by administering the antitumor agent temozolomide in combination with the compound of formula (I). 11. A therapeutic combination comprising: (a) a compound of formula (I): [Claims 1 / 2 page 2 CN 121969369 A] where R is hydrogen or fluorine, and (b) an alkylating agent temozolomide, in the preparation of a medicament for treating glioma. 12. A pharmaceutical composition comprising a combination of compound (a) as defined in claim 1 and agent (b) temozolomide, mixed with a pharmaceutically acceptable carrier, diluent, or excipient. 13. A method of treating a patient with glioma of corresponding need, comprising administering to the patient a therapeutically effective amount of the following combination: (a) a compound of formula (I): [Claims 1 / 2 page 2 CN 121969369 A] where R is hydrogen or fluorine, and (b) an alkylating agent temozolomide. Claims 2 / 2 Page 3 CN 121969369 A Combination of PARP-1 Selective Inhibitor and Temozolomide and Its Use in the Treatment of Glioma

[0001] This invention relates to a therapeutic combination comprising a selected group of PARP-1 selective inhibitors and an alkylating agent, temozolomide (TMZ); and relates to the use of said combination in the treatment of cancer, particularly brain tumors. Background Art

[0002] PARP-1 is a member of the poly(ADP-ribose) polymerase family of enzymes and, together with PARP-2, binds to DNA damage sites and promotes the repair of DNA damage sites by attaching multiple ADP-ribose units to proteins such as histones and various DNA repair enzymes. PARP-1 plays a prominent role in this process.Following PARP-1 inhibition, normal cells effectively repair DNA double-strand breaks, while in cancer cells with DNA repair deficiencies, particularly in homologous recombination repair (HRR), the accumulation of DNA breaks leads to genomic instability and ultimately cell death. PARP inhibitors have indeed demonstrated efficacy as single agents in tumors with HRR deficiencies, including BRCA-mutant (BRCAm) tumors, and olaparib, talazoparib, rucaparib, and niraparib have been approved as single agents for the treatment of breast cancer, ovarian cancer, pancreatic cancer, and prostate cancer (Cortesi L, Rugo HS, Jackisch C. An Overview of PARP Inhibitors for the Treatment of Breast Cancer. Target Oncol. 2021, 16(3), 255-282; Priyancy G. Jain, Bhumika D. Patel, Medicinal chemistry approaches of poly ADP-Ribose). Polymerase 1 (PARP-1) inhibitors as anticancer agents – A recent update, European Journal of Medicinal Chemistry, 2019, 165, 198-215. Furthermore, PARP inhibitors, in combination with DNA-damaging agents such as alkylating agents, topoisomerase inhibitors, and platinum derivatives, have potentially limitless applications in all cancers. Despite significant benefits, PARP inhibitors have shown some undesirable side effects, particularly cytopenia, and to date, combinations of these drugs with DNA-damaging agents have been limited by overlapping hematologic toxicities.All approved PARP inhibitors have limited selectivity for PARP-1 relative to PARP-2 (Ying-Qing Wang, Ping-Yuan Wang, Yu-Ting Wang, Guang-Fu Yang, Ao Zhang and Ze-Hong Miao. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy. J. Med. Chem. 2016, 59 (21), 9575-9598). It has been demonstrated that PARP-2 inhibition is unnecessary for antitumor activity and, alternatively, plays a crucial role in the survival of hematopoietic cells (Farrés J, Martín-Caballero J, Martínez C, Lozano JJ, Llacuna L, Ampurdan és C, Ruiz-Herguido C, Dantzer F, Schreiber V, Villunger A, Bigas A, Yélamos J. Parp-2 is required to maintain hematopoiesis following sublethal γ-irradiation in mice. Blood. 2013, 4;122(1), 44-54), suggesting that PARP-2 inhibition may drive the hematological toxicities observed with approved non-selective PARP inhibitors. Therefore, compounds with high selectivity for PARP-1 are expected to exhibit lower toxicity, particularly in combination with chemotherapy, expanding the therapeutic options for these inhibitors.

[0003] Patent application WO2014064149 under the name of the applicant describes certain 4-formamide-isoindolinone derivatives as selective PARP-1 inhibitors.

[0004] Brain tumors are among the types of cancer with the highest medical needs, and they remain incurable with no significant improvement in outcomes as described in the specification 1 / 8 page 4 CN 121969369 A. Glioblastoma is the most common type of brain tumor, and its average life expectancy from initial diagnosis is no more than 14-15 months. Temozolomide is a widely used first-line treatment for brain tumors; however, its efficacy is limited, and resistance develops very rapidly, especially in patients with glioblastomas that have unmethylated methylguanine DNA-methyltransferase (MGMT) promoters.In patients with relapse, treatment options are particularly limited, and the median overall survival is 9–10 months (Schaff LR, Mellinghoff IK. Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. JAMA. 2023, 329(7), 574–587). Non-selective PARP inhibitors, such as olaparib (OPERATIC trial) and veliparib (NCT01026493, NCT02152982), have been investigated in clinical trials in patients with brain tumors; however, due to dose reduction, the combination has shown high myelosuppression and low potency. Therefore, there is a need for PARP inhibitors with higher selectivity, high brain penetration and lower hematologic effects to improve combination potency.

[0005] The present invention addresses these needs by providing a new combination of a selected set of selective PARP-1 inhibitors with alkylating agents, particularly with temozolomide. These combinations have been found to be suitable for the treatment of tumors of the central nervous system, particularly gliomas and more particularly glioblastomas. The combinations of the present invention are very useful as antitumor agents in therapy and do not have the disadvantages associated with currently available antitumor drugs in terms of toxicity and side effects. Therefore, the combination provides significant synergistic effects and prolonged tumor regression activity without a corresponding increase in toxicity. Description of the Invention

[0006] The present invention provides a combination of two anticancer drugs to achieve synergistic effects. It has now been found that PARP-1 inhibitors, more particularly compounds of formula (I), or a specific combination of the PARP-1 inhibitor, a compound of one of pharmaceutically acceptable salts of an acid or base, with the alkylating agent temozolomide, effectively deliver tumor regression and antitumor activity against glioblastomas.

[0007] In a first aspect, the present invention relates to a therapeutic combination comprising: (a) a compound of formula (I):

[0008] wherein R is hydrogen or fluorine, and (b) an alkylating agent temozolomide, for use in the treatment of gliomas, wherein the active ingredient is present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof.

[0009] In a preferred embodiment, the compound of formula (I) is 2-(1-cyclohexylpiperidin-4-yl)-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (compound 1):

[0010] These compounds and their preparation methods have been described in WO2014064149 under the name of Nerviano Medical Sciences.Pharmaceutically acceptable salts of compounds of formula (I) include acid addition salts with inorganic or organic acids, such as nitric acid, hydrochloric acid, hydrobromic acid, sulfuric acid, perchloric acid, phosphoric acid, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, lactic acid, oxalic acid, malonic acid, malic acid, maleic acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, hydroxyethanesulfonic acid, salicylic acid, etc.

[0011] Advantageously and surprisingly, the application of the above-described combinations of the present invention provided synergistic effects in in vitro brain tumor-derived cell lines and provided highly effective control of tumor growth in a glioblastoma mouse model. In particular, as shown in the experimental section (Tables 1 and 2), such combined treatments provided synergistic effects and strong delays in tumor growth when compared with groups treated with the medium and groups treated with a single agent. Furthermore, to date, tumor shrinkage and / or RANO response have been observed in some patients in Phase 1 studies, and the overall trend of the association between compound 1 exposure and tumor changes in the studies suggests a specific effect of the combination of the present invention.

[0012] In another aspect, the present invention also includes the use of the combination of the compound (a) and agent (b) described above in the preparation of a medicament for treating glioma.

[0013] In another aspect, the present invention relates to a method of treating glioma in a patient with a corresponding need, the method comprising administering to the patient a therapeutically effective amount of the combination of the compound (a) and agent (b) as described above.

[0014] All the above combinations, uses, and methods can be performed indiscriminately by administering the compound (a) and agent (b) simultaneously, separately, or sequentially; said combinations, uses, and methods can be performed by administering the compound (a) and agent (b) as the compound itself or as a pharmaceutical composition (wherein the compound (a) and agent (b) can be formulated together or separately). When not administered simultaneously, the compound and agent can be administered in any order.

[0015] In yet another aspect, the present invention provides a pharmaceutical composition comprising a combination of the compound (a) and agent (b) described above, mixed with a pharmaceutically acceptable carrier, diluent, or excipient.

[0016] According to a preferred embodiment of the invention, glioma is glioblastoma.

[0017] Temozolomide can be administered, for example, in its commercially available form, such as in the commercially available form of the trademark TEMODAR.

[0018] In the present invention, the amount of each of the combined active ingredients effectively produces a synergistic antitumor effect.

[0019] The term "synergistic antitumor effect" as used herein means the inhibition of tumor growth or delay of its progression by administering an effective amount of a compound of formula (I) as defined above and the alkylating agent TMZ to a mammal (including a human).

[0020] The term "treatment combination" as used herein also includes articles in the form of a "kit of parts," wherein combination partners (a) and (b) as defined above can be administered independently or by using different fixed combinations of combination partners (a) and (b) in different amounts, i.e., simultaneously or at different time points. The parts of the kit of parts can then be administered, for example, simultaneously or in staggered chronological order, i.e., at different time points and at the same or different time intervals for any part of the kit of parts. Very preferably, the time intervals are chosen such that the effect on the disease being treated by the combined use of the parts is greater than the effect that would be obtained by using either combination partner (a) or (b) alone. The ratio of the total amount of combination partner (a) to the total amount of combination partner (b) to be administered in the combination article can be varied, for example, to meet the needs of a subgroup of patients to be treated or the needs of an individual patient, which may be due to the patient's specific disease, age, sex, weight, etc. There is at least one beneficial effect, for example, the mutual enhancement of the effects of the combination partners (a) and (b), especially the synergistic effect, such as exceeding the additive effect, additional beneficial effect, fewer side effects, the combined therapeutic effect of one or both of the combination partners (a) and (b) at ineffective doses, and very preferably the strong synergistic effect of the combination partners (a) and (b).

[0021] The effect of the combination of the present invention is significantly increased without a parallel increase in toxicity. In other words, the combination therapy of the present invention enhances the antitumor effect of the combination partners (a) and / or (b) of the present invention, and thus produces the most effective and less toxic tumor treatment.

[0022] Furthermore, the combination of partners (a) and (b) provides the additional advantage of a longer tumor regression activity after administration, 3 / 8 pages of the specification 6 CN 121969369 A, which is not reflected in a corresponding increase in toxicity to the organism.

[0023] As used herein, the terms “administered” or “administering” mean parenteral administration and / or oral administration. "Parenteral" means intravenous, subcutaneous, and intramuscular administration.

[0024] In the method of the present invention, the course of treatment for the administration of the compound of formula (I) is generally in the range of 1 mg / day to 1 g / day, calculated as free base. More preferably, the course of treatment is from about 40 mg / day to about 260 mg / day, calculated as free base.Typical regimens include the following administration schedule: daily for up to 21 consecutive days; daily for 7 consecutive days, followed by a three-week rest period, for a total of 28-day cycles (four-week cycles); daily for 14 days, followed by a one-week rest period (three-week cycles); daily from day 1 to day 7 and from day 15 to day 21 of the four-week cycle; continuing until disease progression, the compound of formula (I) may be administered once or twice daily. In a preferred embodiment, the compound of formula (I) is administered twice daily.

[0025] The compound of formula (I) may be administered in a variety of dosage forms, such as oral administration, in the form of tablets, capsules, sugar or film-coated tablets, liquid solutions or suspensions; rectal administration, in the form of suppositories; parenteral administration, such as intramuscular administration, or by intravenous and / or intrathecal and / or spinal injection or infusion. In a preferred embodiment, the compound of formula (I) is administered orally.

[0026] In the method of the present invention, the course of treatment for the administration of the alkylating agent TMZ is typically from 15 mg / m2 to 300 mg / m2 per day. More preferably, the course of treatment is typically from about 50 mg / m2 to 200 mg / m2 per day. Most preferably, the course of treatment is typically from about 150 mg / m2 to 200 mg / m2, for up to 7 consecutive days every 28 days, wherein TMZ is preferably administered orally.

[0027] The present invention also provides a commercial package (multipart kit) comprising: (a) a compound of formula (I) as defined above and an agent (b) as described above in a suitable container, wherein the active ingredient is present in each case in free form or in the form of its pharmaceutically acceptable salt or any hydrate, and instructions for use of them simultaneously, separately or sequentially. In the package according to the invention, each of the partners (a) and (b) is present in a single container or in different container devices.

[0028] Another embodiment of the invention is a commercial package comprising the pharmaceutical composition or product as described above.

[0029] The activity of the combinations of the invention has been demonstrated, for example, by the following in vitro and in vivo tests, and is supported by ongoing Phase I clinical results, which are intended to be illustrative rather than limiting. Examples

[0030] Evaluation of in vitro synergistic effects: Materials and methods. Human glioma cell lines U-138-MG, LN-18, LN-229, and T98G, all purchased from ATCC, were cultured in EMEM (U-138-MG, T98G) or DMEM (LN-18, LN-229) supplemented with 10% FBS, respectively, isolated twice weekly, and subjected to routine tests to verify the absence of mycoplasma contamination.U-138-MG, LN-18, and LN-229 cells were seeded at different cell densities in 96-well black microplates containing 200 μl / well of appropriate culture medium, allowing the cells to remain actively proliferating at the end of the experiment. Cells were incubated at 37°C in a humidified 5% CO2 atmosphere for 24 hours, and then simultaneously treated with compound 1 alone or temozolomide or a combination of matrices using a digital dispenser D300e (Tecan). After 144 hours of drug treatment, cells were lysed in the 96-well plates using 50 µl / well of CellTiter Glo reagent solution (Promega). After mixing for 10 minutes, the plates were analyzed using a luminescent plate reader (EnVision, PerkinElmer). The antiproliferative activity of the compounds was measured using the CellTiter Glo cell viability assay (Promega), a luciferase-based assay that assesses the number of metabolically active cells by quantifying ATP. Instructions for Use, Page 4 / 8, CN 121969369 A

[0031] T98G cells were seeded at a density of 1000 cells / well in 96-well black culture microplates and incubated at 37°C in a humid 5% CO2 atmosphere for 48 hours prior to treatment.

[0032] A solution of compound 1 or temozolomide, alone or in combination, was directly applied to the cells using a D300e digital dispenser (Tecan). After treatment, the plates were incubated for 144 hours until cell colonies were clearly visible. The growth medium was then removed, and the cells were fixed with 3.7% paraformaldehyde solution. After incubation at room temperature for 20 minutes, the colonies were stained with 30 μl / well of 1% crystal violet solution (SIGMA) for approximately 20 minutes. After washing several times with distilled water to remove excess dye, the plates were allowed to dry at room temperature and then analyzed using an Odyssey (Li-COR) plate scanner. Images of the collection plates were collected, and the average fluorescence intensity per well, proportional to the number and size of cell colonies, was measured as a reading.

[0033] Cell viability data were analyzed according to the Bliss-independent model described below. Combination experiments were performed in duplicate (two technical replicates each), and for each combination experiment, an additional untreated sample was seeded onto the assay plate, and their ATP levels were measured by adding CellTiter Glo at compound treatment (T0). These data points represent T0 values ​​for growth inhibition determination.

[0034] Combination data are expressed as survival fractions (FS) relative to the DMSO-treated control (CTR): FS = treated sample / CTR and analyzed according to the Bliss-independent model.Assuming that compound 1 and temozolomide act independently, the model predicts the combined effect as the product of the effects of its components according to the following equation: FUAB = FUA * FUB where FUA and FUB are separate fractions unaffected by the two agents (A and B).

[0035] The combination index is calculated as the ratio between the experimentally measured survival value (FS) and the predicted combination value.

[0036] Bliss CI = FSAB / FUAB Combination Index (CI) ≤ 0.8 indicates synergistic effect; 0.8–1.2 indicates additive effect; ≥ 1.2 indicates antagonistic effect.

[0037] When two substances are used in a certain concentration range, a clear combined effect can usually be assessed, such as inducing 15%–90% cell viability as a single agent compared to an untreated control. Outside this range, data may be affected by experimental variability. Therefore, the CI of a combination in which the same dose of the two compounds kills >85% of cells as a single agent (producing less than 15% residual cell viability) is considered unmeasurable for in vitro combined effects (“NE”). Conversely, combinations of compounds in which the same dose of a single agent showed no effect (resulting in cell viability exceeding 90%) were considered only if they produced a significant synergistic or antagonistic effect; if the effect was additive, they were considered unevaluable (“NE”). By convention, in order to be able to evaluate the effect of a combination of two compounds, we assume that at least three points in the combination matrix must be effective (i.e., combinations whose single agents have an effect resulting in cell viability between 15% and 90%).

[0038] The in vitro combination of compound 1 with temozolomide was tested in glioma cell lines U-138-MG (astrocytoma, MGMT unmethylated), LN-18 (glioblastoma, MGMT unmethylated), LN-229 (glioblastoma, MGMT methylated), and T98G (glioblastoma, MGMT unmethylated). The combination produced a synergistic effect in all tested cell lines (Table 1).

[0039] Table 1: In vitro combined action of compound 1 and TMZ in glioma cell lines after 144 h of treatment. Specification 5 / 8 pages 8 CN 121969369 A

[0040]

[0041] Evaluation materials and methods for tumor growth inhibition and in vivo toxicity.

[0042] In accordance with European Community Commission Directive 86 / 609 / EEC, Scid naked female mice from CRI were kept in cages with paper filter covers, food and sterile bedding, and acidified water. Fragments of T98G human glioblastoma cells were subcutaneously implanted. Treatment was initiated when the tumor was palpable.

[0043] The compound of formula (I) was administered orally at a volume of 10 ml / kg at the indicated dose from day 1 to day 8. Temozolomide was administered orally at a dose of 50 mg / kg for 6 consecutive days. When combined, the compound of formula (I) was administered from day 1 to day 8, and TMZ was administered from day 3 to day 8. Tumor growth and body weight were measured every 3 days. Tumor growth was assessed by calipers. Two diameters were recorded, and tumor weight was calculated according to the following formula: length (mm) × width² / 2. The effect of antitumor treatment was evaluated as the delay in the onset of exponential tumor growth (see reference Anticancer drugs 7:437-60, 1996). This delay (T-C value) was defined as the difference in days required for the tumor in the treatment group (T) and the control group (C) to reach the predetermined size (1 g). Toxicity was evaluated based on the number of animals that died during the experiment.

[0044] For the T98G human glioblastoma xenograft model, the results obtained using the drug as a single agent and in combination with temozolomide are shown in Table 2.

[0045]

[0046] *Oral treatment performed on days 1 to 8.

[0047] **Oral treatment performed on days 3 to 8.

[0048] ***Treatment with compound 1 on days 1 to 8, and treatment with TMZ on days 3 to 8.

[0049] The maximum tumor growth inhibition value observed with compound 1 as a single agent was 22% on day 28 and decreased to 13% on day 40, with no toxicity. Temozolomide alone produced a maximum tumor growth inhibition of 58% on day 40. Combinations of Compound 1 at 25 mg / kg and 50 mg / kg with temozolomide showed 86% and 90% maximum tumor growth inhibition, respectively, on day 40, with a super-additive effect (T-C = 27.7 days and 29 days, compared to 0.5 days with Compound 1 alone and 6.9 days with temozolomide alone).

[0050] In the T98G human glioblastoma xenograft model, the T-C observed when Compound 1 was combined with TMZ was higher than the T-C expected from the simple sum of T-Cs obtained by single treatments, indicating a strong synergistic effect. No toxicity was observed in either treatment group.

[0051] Preliminary clinical data: As of the data cutoff of August 20, 2024, 30 patients with measurable high-grade gliomas who had relapsed after first-line therapy including standard care with temozolomide had been treated within the dose range of Compound 1 and had received at least one treatment radiological evaluation. Within the dose range, the overall trend reported by investigators regarding the association between compound 1 exposure and treatment duration, tumor stabilization and shrinkage, and even complete tumor disappearance has been highlighted.In the study, three patients with glioblastoma reported investigator-assessed complete tumor disappearance. One patient treated with 50 mg twice daily (BID) showed complete disappearance of baseline enhancing lesions and maintained treatment for 10.9 months. Another patient with methylated MGMT, treated with 100 mg BID, showed very rapid disappearance of baseline tumors only 15.6 weeks after treatment initiation, coded as a complete response (CR). Response in baseline target lesions has persisted for 4.3 months. The last patient, also treated with 100 mg BID, had epidermal growth factor receptor (EGFR) amplification and unmethylated MGMT, a molecular characteristic confirmed by central testing, with a poor prognosis and the lowest chance of responding to TMZ alone, where the expected overall response rate (ORR) in the first line was no more than 7.2% (Omuro et al., Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro Oncol. Jan 5, 2023;25(1):123-134. doi: 10.1093 / neuonc / noac099.) (therefore, the rate of treatment failure is much lower, as in the described patients). Instead, the described patients had a very well-tolerated treatment profile, with no treatment-emergent adverse events (TEAEs) equal to or higher than G3, demonstrating progressive shrinkage of the baseline-enhancing tumor burden until investigator-assessed sustained complete tumor disappearance, meeting RANO CR, which was still ongoing at the data cutoff, with a duration of response exceeding 6.2 months. Throughout the clinical development program, apart from QTc prolongation, compound 1 has not shown a trend toward dose-related adverse events, and to date, QTc prolongation has not caused cardiac conduction-related clinical events / sequelae or QT-related arrhythmias. Overall, no dose-dependent trend toward myelosuppression was observed across multiple cycles of continuous treatment. In the trial exposing 23 patients with high-grade gliomas to a range of doses of compound 1, no serious adverse events or any adverse events leading to treatment discontinuation have been reported.Table 3 reports the most common (≥10%) treatment-emergent adverse events (TEAEs) as of the data cutoff of August 20, 2024, and the categories (N=45) of TEAEs involving at least two patients in the total population with either compound 1 or compound 1 and TMZ or TMZ-related TEAEs: Table 3 Product Information 7 / 8 Page 10 CN 121969369 A

[0052] Patients in all categories who experienced TEAEs in ≥10% of the total population or had at least two cases of TEAEs involving either compound 1 / TMZ or compound 1 or TMZ may have experienced the same AE with different causal relationships during treatment. § Decreased platelet count and thrombocytopenia are counted in the same group. # Decreased neutrophil count and neutropenia are counted in the same group. & Decreased white blood cell count and leukopenia are counted in the same group. Product Information 8 / 8 Page 11 CN 121969369 A.

Claims

1. A treatment combination comprising: (a) Compounds of formula (I): Where R is hydrogen or fluorine, and b) The alkylating agent temozolomide is used in the treatment of glioma, wherein the active ingredient is present in each case either in free form or as a pharmaceutically acceptable salt or any hydrate thereof.

2. The therapeutic combination for use according to claim 1, wherein the compound of formula (I) is 2-(1-cyclohexylpiperidin-4-yl)-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (compound 1): 。 3. The treatment combination for use according to any one of claims 1 or 2, wherein the glioma is a glioblastoma.

4. The treatment combination for use according to any one of claims 1 to 3, for simultaneous, separate or sequential application.

5. The treatment combination for use according to any one of claims 1 to 4, wherein the combination is formulated as a pharmaceutical composition.

6. The treatment combination for use according to any one of claims 1 to 5, in the form of a multi-part kit, the multi-part kit comprising: the agent (a) and the agent (b) in a suitable container, and instructions for use of the agent (a) and the agent (b) simultaneously, separately or sequentially.

7. The treatment combination for use according to any one of claims 1 to 6, wherein the dosage of the compound of formula (I) is from 1 mg / day to 1 g / day, and the dosage of temozolomide is from 15 mg / m² / day. 2 Up to 300 mg / m 2 .

8. The treatment combination for use according to claim 7, wherein the dosage of the compound of formula (I) is from 40 mg / day to 260 mg / day, and the dosage of temozolomide is from 150 mg / day. 2 Up to 200 mg / m 2 .

9. The therapeutic combination for use according to any one of claims 1 to 8, wherein the compound of formula (I) is administered orally.

10. A compound of formula (I) as defined in claim 1, for use in reducing side effects caused by the alkylating agent temozolomide, said reduction of side effects being obtained by administering the antitumor agent temozolomide in combination with a compound of formula (I).

11. A treatment combination comprising: (a) Compounds of formula (I): Where R is hydrogen or fluorine, and b) Temozolomide, an alkylating agent, in the preparation of a drug for the treatment of glioma.

12. A pharmaceutical composition comprising a combination of the compound (a) as defined in claim 1 and the agent (b) temozolomide, mixed with a pharmaceutically acceptable carrier, diluent, or excipient.

13. A method of treating glioma in a patient with a corresponding need, comprising administering to the patient a therapeutically effective amount of the following combination: (a) Compounds of formula (I): Where R is hydrogen or fluorine, and b) Alkylating agent temozolomide.